-
Patent Term Adjustment and Drug Patent Term Extension after Amendment to Chinese Patent Law
As we reported in our October 2020 and May 2021 Newsletters, the Fourth Amendment to Chinese Patent Law has become effective from June 1, 2021. In this regard, we want to draw your attention to the following two provisions in the new Patent Law.Article 42.2 For patents granted after four (4) years from the application date and three (3) years from date of request fo
2021-06-11 -
Temporary Rules regarding Examination Work after Implementation of the Amended Chinese Patent Law (Published on May 24, 2021 by CNIPA, Effective from June 1, 2021)
As we reported in our October 2020 Newsletter, the Fourth Amendment to Chinese Patent Law (the Amendment) will be effective from June 1, 2021. We had expected that the corresponding amendments to the Implementing Regulations of the Chinese Patent Law and the Patent Examination Guidelines would have been enacted before June 1, 2021. However, they have not as of late May
2021-05-31 -
Main Points of the Fourth Amendment to Chinese Patent Law (Approved on October 17, 2020, effective from June 1, 2021)
China’s National People’s Congress has approved the Fourth Amendment to Chinese Patent Law on October 17, 2020. The amended law will be effective from June 1, 2021. We also expect that the Implementing Regulations of the Chinese Patent Law and the Patent Examination Guidelines will also be amended accordingly, before the effective date of the amended law. These regulation
2020-10-26 -
First Ever Preliminary Injunction Issued by Chinese Court in Pharmaceutical Patent Case
The Beijing IP Court has issued a preliminary injunction against a patent infringer in a pharmaceutical case earlier this year. As far as we know, this is the first time that such an injunction is ordered by a Chinese court in a pharmaceutical patent case. As we briefly discuss below, the case will have huge implications for not only the pharmaceutical industry, but patent protecti
2020-04-27 -
Record Amount of Damages Requested in Chinese Patent Case
A patent infringement dispute between two Chinese companies has seen a total amount of RMB 1 billion (about US$ 150 million) damages requested, a record for a Chinese patent infringement case.
2019-04-26
Our professionals include some of the most experienced and committed practitioners in their profession. Our attorney’s cross-domain specializations allow for seamless customized intellectual property solutions for clients’ needs.
Our people are the key to providing the full range of service capabilities our clients need by working together as integrated, multidisciplinary teams with each member drawing from a unique set of talents.
We invite you to review the wide range of their qualifications and capabilities.
Share
-
Beijing Office
-
Hong Kong Office
-
Singapore Office
-
Washington D.C. Office
-
Tokyo Office
-
Munich Office
Tel: +86-10-6657 6688
Fax: +86-10-6657 8088
E-mail: sinda@chinasinda.com Backup e-mail: (from May 18, 2021) sinda@chinasinda.com.cn
11/F, Tower B, Focus Place
19 Financial Street
Beijing 100033, P.R. China
Tel: +852-21109911
Fax: +852-21109973
E-mail: mail@csiphk.com; patent@csiphk.com; hk@chinasinda.com
Suite 3301 One Exchange Square
Central, Hong Kong
Tel: +65-62228501
Fax: +65-62228505
E-mail: weilin.zhang@chinasinda.com Backup emails: mail@chinasinda.sg zhang_weilin@outlook.com
133 Cecil Street
#12-01A Keck Seng Tower
Singapore 069535
Suite 205
17B Firstfield Road
Gaithersburg, MD 20878
USA
5-35-4 2F Sakurajosui, Setagaya-ku,
Tokyo, 156-0045 Japan
Tel: +49-89-90405037
Fax: +49-89-90405066
E-mail: munich@chinasinda.com
Regus Business Center
Landsberger Str. 302
80687, Munich, Germany
